Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05275478 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
A Phase 1 study of Locally Advanced Solid Tumor, sponsored by Tango Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 192
- Enrollment target
- 20
- Study locations
NCT05275478: Active Phase 1 study of Locally Advanced Solid Tumor, sponsored by Tango Therapeutics.
NCT05275478 is a Phase 1 study of Locally Advanced Solid Tumor that is active but no longer recruiting, run by Tango Therapeutics. The registered enrollment target is 192 participants, below the 226-participant average among 13 other Locally Advanced Solid Tumor trials with a reported enrollment target (15% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05275478, a Phase 1 study of Locally Advanced Solid Tumor, is active but no longer recruiting, sponsored by Tango Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 192 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG908, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 192 participants.
Primary Outcome
To determine the MTD and dosing schedule of TNG908
Conditions Studied
Interventions
- DRUG TNG908
Study Locations (20)
Other
- Institut Bergonié - Bordeaux
- Centre Léon Bérard - Lyon
- EDOG Institut de Cancerologie de l'Ouest - Saint-Herblain
- Institut Oncopole Claudius Regaud - Toulouse
- Institute Gustav Roussy - Villejuif
California
- University of California Los Angeles - Los Angeles
- University of California San Francisco - San Francisco
Colorado
- Sarah Cannon Research Institute at HealthONE - Denver
- Grand Valley Oncology - Grand Junction
Illinois
- Northwestern University - Chicago
- Carle Cancer Center - Urbana
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
New York
- NYU Langone Health - New York
- Memorial Sloan Kettering Cancer Center - New York
Florida
- Florida Cancer Specialists & Research Institute - Lake Mary
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2022-03-23 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
What the registry record for NCT05275478 still lists
NCT05275478 is an interventional study that assigns participants to a tested intervention. The registered 192 participants enrollment target is mid-sized for trials with a published cap, below the 226-participant average among 13 other Locally Advanced Solid Tumor trials with a reported enrollment target (15% lower).
The record links to 1 condition, with Locally Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which TNG908 is the first listed.
NCT05275478 names 20 study sites across 11 states, led by Other, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT05275478 about?
NCT05275478 is a clinical study titled "Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors". This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG908, is a sel...
What is the current status of trial NCT05275478?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 192 participants. The study started on 2022-03-23. Estimated completion is 2025-12.
What conditions does trial NCT05275478 study?
This clinical trial studies the following conditions: Locally Advanced Solid Tumor.
What interventions are being tested in trial NCT05275478?
The interventions under investigation include: TNG908 (DRUG).
Who is sponsoring clinical trial NCT05275478?
This trial is sponsored by Tango Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05275478 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05275478's enrollment target sits among peer trials
192 7th of 13 higher than 7 of 13 other Locally Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Locally Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
RECRUITING · Phase 1
-
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
RECRUITING · Phase 1
-
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
RECRUITING · Phase 1
-
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
RECRUITING · Phase 1
-
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
- NCT02535702 · 192 participants · NA
Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction
- NCT03622359 · 192 participants · NA
Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI